Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avalon GloboCare ( (ALBT) ) just unveiled an announcement.
On January 20, 2026, Avalon GloboCare announced that Qi Diagnostics Limited has renewed the U.S. Food and Drug Administration establishment registration for KetoAir™, a handheld nanosensor-based breathalyzer used for ketogenic health management that measures breath acetone to provide real-time, non-invasive insight into users’ metabolic state via iOS and Android companion apps. Avalon plans to leverage its Catch-Up™ automated generative AI-powered short-form video SaaS platform, operated through subsidiary Avalon Quantum AI, LLC, to launch KetoAir™ into both business-to-business and business-to-consumer channels starting in the second quarter of 2026, a move aimed at creating scalable, cost-efficient marketing pathways to accelerate market adoption and strengthen the company’s positioning in digital health and consumer diagnostics.
More about Avalon GloboCare
Avalon GloboCare Corp. (NASDAQ: ALBT) is a diversified company focused on precision diagnostic consumer products, advancing intellectual property in cellular therapy, and generative artificial intelligence publishing and software, while also owning and operating commercial real estate. The company currently markets the KetoAir™ FDA-registered Class I medical device breathalyzer and plans to develop additional diagnostic applications based on its breath analysis technology, supported by a growing intellectual property portfolio.
Average Trading Volume: 86,027
Technical Sentiment Signal: Sell
Current Market Cap: $5.33M
For detailed information about ALBT stock, go to TipRanks’ Stock Analysis page.